Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager

This study is about people who have multiple myeloma, a type of blood cancer, especially those whose cancer has come back (relapsed) or is no longer responding to standard treatments. There are some exciting new treatments called BCMA-directed T-cell engagers that are helping many patients. However, a common problem with these new treatments is that they can make your immune system weaker, which means you are more likely to get infections. Patients with multiple myeloma often already have a weaker immune system, so these new drugs can make this situation even more challenging.

To help prevent severe infections, doctors sometimes give patients extra proteins called immunoglobulins, which are a key part of your immune system. While we know immunoglobulins can be helpful, we're not entirely sure if everyone receiving these new BCMA-directed treatments needs them, or what the ideal amount of immunoglobulin in the blood should be to offer the best protection against infections. This study aims to answer those important questions.

The main goal of this research is to compare two different target levels of immunoglobulins in the blood to find out which one is better at preventing severe infections after three months. One group of patients will aim for a lower target level (4-6 g/L) and another group will aim for a higher target level (8-10 g/L). By understanding this, doctors will have better guidance on how to support patients and reduce their risk of serious infections while they are on these powerful new myeloma treatments.